Vidal Therapeutics

Orna Therapeutics is a biotechnology company pioneering a new class of RNA medicines based on circular RNA, which they call oRNA. Unlike linear mRNA, oRNA is engineered to be more stable, more potent, and easier to manufacture due to its circular structure which resists exonuclease degradation. The company's proprietary platform combines oRNA with custom lipid nanoparticles to enable in situ CAR-T therapies and treatments for genetic diseases. Orna's lead program, ORN-101, is an in situ CAR-T therapy targeting CD19 for the treatment of B-cell lymphomas, designed to create CAR-T cells directly inside the patient's body. In 2024, the company expanded its capabilities by acquiring ReNAgade Therapeutics, integrating advanced delivery technologies to broaden its reach into extrahepatic tissues. Orna is backed by a strong syndicate of investors including Flagship Pioneering and has a significant strategic collaboration with Merck.